Market Place
Sourcing Support
All News #Library
Others
Mabwell to Present 9MW2821 Data for Cervical Cancer at ESMO 2026
30 Apr 2026 //
PR NEWSWIRE
Annualized Severe COPD Exacerbation Rate Reduced by Over 40%
01 Dec 2025 //
PR NEWSWIRE
Mabwell Unveils New Clinical Data On B7-H3-Targeting ADC 7MW3711
14 Oct 2025 //
PR NEWSWIRE
Mabwell Starts US Study Of Bulumtatug Fuvedotin In TNBC Patients
12 Aug 2025 //
PR NEWSWIRE
Mabwell License Agreement Albipagrastim to Qilu Pharmaceutical
27 Jun 2025 //
PR NEWSWIRE
Highlights in Oral Presentation of Mabwell`s 9MW2821 at 2025 ASCO
05 Jun 2025 //
PR NEWSWIRE
Mabwell Releases 6 Study Results at 2025 AACR Annual Meeting
30 Apr 2025 //
PR NEWSWIRE
Mabwell’s 9MW2821 Gets Breakthrough Therapy For Urothelial Cancer
09 Jan 2025 //
CONTRACTPHARMA
Mabwell Reveals Pre-clinical 7MW4811 Data at World ADC Conference
08 Nov 2024 //
PR NEWSWIRE
Mabwell`s 9MW2821 Approved For Phase III Trial In Urothelial Carcinoma
26 Aug 2024 //
PR NEWSWIRE
Mabwell: Innovative Drugs Preclinical Data At AACR 2024
16 Apr 2024 //
PR NEWSWIRE
Mabwell to Present Pre-clinical Results at the 2024 AACR Annual Meeting
12 Mar 2024 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.